SCHEMBL2655693

SCHEMBL2655693

COc1ccc(Nc2cccc(N3CCN(C(C)=O)CC3)c2)c(N)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.52
NPC1 O15118 1/20 0.52
GFER P55789 1/20 0.52
SYK P43405 1/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA9 Q16790 2/20 0.49
KMT2A Q03164 5/20 0.47
MEN1 O00255 3/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
EGFR P00533 1/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199937 0.88 SCN9A (0.45) GAAEGFRLMNASMN1; SMN2HSD17B10
SCHEMBL2653555 0.86 NPC1 (0.49) GAANPC1GFERSYKCA12
SCHEMBL2655735 0.85 MAPT (0.48) GAANPC1GFERKMT2AMEN1
SCHEMBL2654223 0.84 AKR1C3 (0.60) GAAKMT2AMEN1POLBSMN1; SMN2
SCHEMBL2654981 0.84 SMN1; SMN2 (0.51) GAAGFERSYKEGFRLMNA
SCHEMBL2656292 0.82 LMNA (0.52) GAAGFERKMT2AMEN1POLB
SCHEMBL2655224 0.81 CCNT1 (0.45) GAAGFERSYKKMT2AMEN1
SCHEMBL2653592 0.81 MAPT (0.43) GAANPC1GFEREGFRSMN1; SMN2
SCHEMBL8321177 0.80 KMT2A (0.63) GAANPC1CA12CA1CA2
SCHEMBL4202254 0.80 KDM4E (0.42) GAAGFERKMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062304-A1 Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex NEUROSEARCH A/S (DK) 2009-03-05 US disclosed
EP-1874735-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2008-01-09 EP disclosed
WO-2006111517-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062304-A1 Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex GABRB1, GABRB2, GABRB3 GAA 932/4885NPC1 1879/4885GFER 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.